INMB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.270

-32.5%

-0.307

-28.68%

-0.287

-72.7%

Estimates Revision

The market is revising Upward the revenue expectations for INmune Bio, Inc. (INMB) for FY2025, with the revenue forecasts being adjusted by 20.01% over the past three months. During the same period, the stock price has changed by -19.89%.

Revenue Estimates for FY2025

Revise Upward

+20.01%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-10.34%

In Past 3 Month

Stock Price

Go Down

-19.89%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast INMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMB is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Alliance Global Partners

Buy

downgrade

$20 -> $7

2025-07-03

Reason

Alliance Global Partners

Price Target

$20 -> $7

2025-07-03

downgrade

Buy

Reason

Alliance Global Partners lowered the firm's price target on INmune Bio to $7 from $20 and keeps a Buy rating on the shares after the company reported topline Phase 2 data from the MINDful trial of XPro for Alzheimer's disease that "were not what we had hoped for." The firm adjusted its price target to account for the added uncertainly around the future development for XPro and the additional time that will be needed to find a partner and start confirmatory trials, noting that it now values XPro for Alzheimer's at $3 per share.

Maxim

Jason McCarthy

Buy

downgrade

$30 -> $8

2025-07-02

Reason

Maxim

Jason McCarthy

Price Target

$30 -> $8

2025-07-02

downgrade

Buy

Reason

Maxim analyst Jason McCarthy lowered the firm's price target on INmune Bio to $8 from $30 but keeps a Buy rating on the shares. The firm cites the failure of lead drug XPro to demonstrate clinical improvements in the company's Phase 2 Alzheimer's disease trial, but while the top-line data is disappointing, there were some promising aspects and the company continues to develop its pipeline, the analyst tells investors in a research note.

Scotiabank

Outperform -> Underperform

downgrade

$23

2025-07-01

Reason

Scotiabank

Price Target

$23

2025-07-01

downgrade

Outperform -> Underperform

Reason

Scotiabank downgraded INmune Bio to Underperform from Outperform with a price target of 60c, down from $23, based on the failure of lead drug XPro to demonstrate clinical improvements in the company's Phase 2 Alzheimer's disease trial. The firm think management's plan of securing CORDStrom FDA approval for treatment of recessive dystrophic epidermolysis bullosa has a "very low chance of success," the analyst tells investors.

BTIG

Buy -> Neutral

downgrade

$21

2025-06-30

Reason

BTIG

Price Target

$21

2025-06-30

downgrade

Buy -> Neutral

Reason

BTIG downgraded INmune Bio to Neutral from Buy and removed the firm's prior $21 price target after XPro Phase 2 data in early Alzheimer's disease, AD. The results marks another failure of anti-inflammatory approaches in the treatment of AD - despite the clear signs of inflammation in the brains of AD patients and the decades of animal work showing that CNS-inflammation is a negative regulator of neuronal and microglial function, the analyst tells investors in a research note.

Raymond James

Gary Nachman

Outperform -> Market Perform

downgrade

2025-06-30

Reason

Raymond James

Gary Nachman

Price Target

2025-06-30

downgrade

Outperform -> Market Perform

Reason

Raymond James analyst Gary Nachman downgraded INmune Bio to Market Perform from Outperform.

Raymond James

Outperform -> Market Perform

downgrade

$23

2025-06-30

Reason

Raymond James

Price Target

$23

2025-06-30

downgrade

Outperform -> Market Perform

Reason

As previously reported, Raymond James downgraded INmune Bio to Market Perform from Outperform and removed the firm's prior $23 price target after XPro Phase 2 data in early Alzheimer's disease "missed the mark." An effect size was shown in a subset of patients with greater neuroinflammation, but the study did not hit the primary endpoint and the firm sees greater risk to this "key program" moving forward, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for INmune Bio Inc (INMB.O) is -1.30, compared to its 5-year average forward P/E of -4.67. For a more detailed relative valuation and DCF analysis to assess INmune Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.67

Current PE

-1.30

Overvalued PE

-2.37

Undervalued PE

-6.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2220.76

Current PS

0.00

Overvalued PS

7321.52

Undervalued PS

-2879.99

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

INMB News & Events

Events Timeline

No data

News

3.5

2025-12-05Globenewswire

INmune Bio Publishes Overview on Future Applications of MSC Therapies

2.0

2025-12-01Globenewswire

INmune Bio Presents New XPro1595 Data for Alzheimer's Disease at CTAD

9.0

2025-09-15Newsfilter

INmune Bio Successfully Completes Initial Commercial Pilot-Scale Production of CORDStrom™ at CGT Catapult

People Also Watch

Frequently Asked Questions

What is INmune Bio Inc (INMB) stock price today?

The current price of INMB is 1.49 USD — it has decreased -2.61 % in the last trading day.

What is INmune Bio Inc (INMB)'s business?

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

What is the price predicton of INMB Stock?

What is INmune Bio Inc (INMB)'s revenue for the last quarter?

INmune Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is INmune Bio Inc (INMB)'s earnings per share (EPS) for the last quarter?

INmune Bio Inc. EPS for the last quarter amounts to -0.24 USD, decreased -60.00 % YoY.

What changes have occurred in the market's expectations for INmune Bio Inc (INMB)'s fundamentals?

How many employees does INmune Bio Inc (INMB). have?

INmune Bio Inc (INMB) has 22 emplpoyees as of January 10 2026.

What is INmune Bio Inc (INMB) market cap?

Today INMB has the market capitalization of 39.61M USD.